Result of AGM

RNS Number : 5117M

Oxford Biomedica PLC

07 May 2015

 

Oxford BioMedica Annual General Meeting

London, UK - 7 May 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

In accordance with Listing Rule 9.6.18 the following resolutions are those which were passed at the meeting concerning special business:

·      Resolution 14: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares; and

·      Resolution 15: to permit the Group to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxfordbiomedica.co.uk.

Certified copies of the document setting out the above resolutions passed at the 2015 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.

The results of the proxy voting in advance of the meeting are shown below.  On the Record Date (5 May 2015) there were 2,568,040,015 1p ordinary shares in issue, each carrying one vote per share.

Resolution	Votes For	Votes at Chairman's Discretion	Votes at other proxy Discretion	Votes Against	Votes Withheld	Total votes cast	Result
Ordinary resolutions
1	1,569,855,529	997,910	3,429,924	44,395	37,743	1,574,365,501	Passed
2	1,568,499,344	1,124,976	3,429,924	1,144,667	166,590	1,574,365,501	Passed
3	1,559,509,773	1,151,115	3,429,924	2,231,914	8,042,775	1,574,365,501	Passed
4	1,565,366,633	998,823	3,429,924	4,512,371	45,191	1,574,352,942	Passed
5	1,565,363,916	998,823	3,429,924	4,513,033	47,246	1,574,352,942	Passed
6	1,565,365,962	998,823	3,429,924	4,503,033	55,200	1,574,352,942	Passed
7	1,565,355,486	996,203	3,429,924	4,512,371	58,958	1,574,352,942	Passed
8	1,569,730,217	1,000,773	3,429,924	116,408	88,179	1,574,365,501	Passed
9	1,559,704,929	1,052,832	3,429,924	2,148,027	8,029,789	1,574,365,501	Passed
10	1,561,084,685	1,108,626	3,429,924	846,210	7,896,056	1,574,365,501	Passed
11	1,561,001,842	1,068,751	3,429,924	966,478	7,898,506	1,574,365,501	Passed
12	1,569,491,544	1,060,845	3,429,924	190,709	192,479	1,574,365,501	Passed
13	1,569,481,603	1,057,412	3,429,924	249,740	146,822	1,574,365,501	Passed
Special resolutions
14	1,568,482,462	1,155,736	3,429,924	1,090,080	207,299	1,574,365,501	Passed
15	1,566,284,325	1,208,555	3,429,924	3,313,737	128,960	1,574,365,501	Passed

The following resolution was taken on a poll called by the Chairman of the Company at the meeting:

·      Resolution 15: to permit the Group to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

The results of the votes cast were as follows:

Votes For	Votes Against	Votes Withheld	Total Votes Cast	Result
1,583,347,994	6,562,802	7,731,340	1,589,910,796	Passed

The number of votes validly cast in relation to Resolution 15 was 1,589,910,796, which constitutes 61.91% of the issued share capital of the Company.

- Ends -

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: [phone]
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton	Tel: [phone]

Notes for editors

About Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector^® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk  and www.oxbsolutions.co.uk .

 

END

 

 

RAGSSUFFWFISEII